Opis działalności
Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better lives. In addition to its clinical development programs focused on cystic fibrosis, Vertex has more than a dozen ongoing research programs aimed at other serious and life-threatening diseases. Founded in 1989 in Cambridge, Mass., Vertex today has research and development sites and commercial offices in the United States, Europe, Canada and Australia. For five years in a row, Science magazine has named Vertex one of its Top Employers in the life sciences.
Zarząd & Rada nadzorcza
| CEO |
| Reshma Kewalramani, M.D. |
| Zarząd |
| Charles F. Wagner, Jr., David Altshuler, Stuart A. Arbuckle, Jonathan Biller, Carmen Bozic, Amit K. Sachdev, Bastiano Sanna, Nia Tatsis, E. Morrey Atkinson, Ph.D. |
| Rada nadzorcza |
| Dr. Jeffrey Leiden, Bruce I. Sachs, Diana McKenzie, Dr. Alan Garber, Dr. Sangeeta N. Bhatia, Lloyd Carney, Reshma Kewalramani, Terrence C. Kearney, Suketu (Suky) Upadhyay |
Dane firmy
| Nazwa: |
Vertex Pharmaceuticals Inc. |
| Adres: |
50 Northern Avenue,Boston, Massachusetts 02210, USA |
| Telefon: |
+1-617-961-7163 |
| Fax: |
- |
| E-mail: |
Investorinfo@VRTX.com
|
| Internet: |
www.vrtx.com/ |
| Przemysł: |
Służba zdrowia |
| Sektor: |
Przemysł Farmaceutyczny |
| Podsektor: |
Przemysł Farmaceutyczny |
| Koniec roku finansowego: |
31.12 |
| Free float: |
82,70% |
| Data IPO: |
24.07.1991 |
